News explainer
Medicare GLP-1 Bridge: eligible Part D members pay $50 a month for Wegovy, Foundayo or Zepbound KwikPen
Key numbers
- Result
- $50 copay for a one-month supply of Wegovy (injection or tablets), Foundayo or Zepbound KwikPen, for eligible Medicare Part D members.
- Date
- Announced May 6, 2026. Running from July 1, 2026 through December 31, 2027.
- Announced by
- CMS: CMS press release, May 6, 2026

What happened
On May 6, 2026, the Centers for Medicare & Medicaid Services announced that eligible Medicare beneficiaries could get certain GLP-1 medications "for $50 per month beginning July 1, 2026, through December 31, 2027" (CMS). The program is a short-term demonstration called the Medicare GLP-1 Bridge.
Covered drugs: Foundayo, Wegovy (injection and tablets) and the Zepbound KwikPen, when used to reduce excess body weight and keep it off. Zepbound vials and single-dose pens are not included (CMS).
Who qualifies: Part D members in a standalone drug plan or a Medicare Advantage HMO or PPO plan with drug coverage, age 18 or older, with a prescriber's prior authorization showing a BMI of 35 or more, or 30 or more with a listed heart, blood pressure or kidney condition, or 27 or more with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. Special Needs Plans are excluded. People taking a GLP-1 for type 2 diabetes, sleep apnea or MASH use their regular Part D coverage instead.
How the $50 works: the Bridge runs outside the Part D benefit, so the Part D deductible does not apply, the copay does not count toward the yearly out-of-pocket limit, and Extra Help does not lower it. Coupons cannot be applied. Each fill is one 28 or 30-day supply; 60 and 90-day fills are not available. Prior authorization decisions come within 72 hours, and approvals are valid through December 31, 2027 (CMS FAQ).
What this means for cost
For an eligible Part D member, $50 a month is lower than any cash price we record. If you do not qualify, these are the cash prices on our records today.
| Option | Cash price on our record | Read |
|---|---|---|
| Wegovy (semaglutide), Novo Nordisk | Pen: $199 a month for the first 2 fills at 0.25 mg or 0.5 mg for new patients, through December 31, 2026, then $349. Pill: $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg. | Maker's page, Nov 6, 2026 |
| Zepbound (tirzepatide), Eli Lilly | KwikPen through LillyDirect: from $299 a month at 2.5 mg, $399 at 5 mg, $449 at higher doses. | Maker's page, Nov 6, 2026 |
| Foundayo (orforglipron), Eli Lilly | Through LillyDirect: from $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at higher doses. | Maker's page, Nov 6, 2026 |
| EmbodyCompounded semaglutide | $79/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| CoreAge RxCompounded semaglutide | $79/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| AgelessRxCompounded semaglutide | $139/mo, medication plus recorded program fee | Date not recorded |
| EmbodyCompounded tirzepatide | $129/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| CoreAge RxCompounded tirzepatide | $129/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| Sprout HealthCompounded tirzepatide | $199 per 4 weeks, medication plus recorded program fee | Recorded Nov 6, 2026 |
Compounded rows are the lowest recorded monthly subtotals among active listings, sorted by price: medication plus any recorded program fee, with other costs such as labs or shipping not included. Compounded medications are not FDA-approved and are not the brand products. Your prescriber decides which drug and strength fit you.
What happens next
Each new prescription
Your prescriber sends the prior authorization; CMS says the decision comes within 72 hours.
December 31, 2027
The Bridge and its prior authorization approvals end. CMS extended it to this date because the BALANCE Model will not launch in 2027 (CMS).
Sources
- CMS press release, $50 monthly GLP-1 access (May 6, 2026), read Nov 20, 2026
- CMS, Medicare GLP-1 Bridge FAQ (page last modified Jul 13, 2026), read Nov 20, 2026
- CMS, Medicare GLP-1 Bridge information for pharmacies, read Nov 20, 2026